Vertex Q3 2026 Call: Revenue Up 12%, Crinetics Added, and a November 30 Decision on Povitacept

Vertex Pharmaceuticals is in the news after its third-quarter 2026 results call on 2 November 2026. On 3 November, Investing.com reported that TD Cowen had raised its price target on the stock, citing growth prospects (Investing.com, 3 Nov 2026). This was also Charles Wagner's last quarterly call as CFO; Jonathan Pool takes over the CFO role on 1 January 2027.

Key takeaways

• Total revenue grew 12% year on year, with US up 10% and international up 16%. Cystic fibrosis (CF) revenue was $3.3 billion, up 8%; ALYFTREK sales were $706 million in the quarter.
• Non-GAAP earnings per share were $4.76 and non-GAAP net income was $1.21 billion. Non-GAAP gross margin was 85.6%.
• Full-year revenue guidance rose to $13.15–13.25 billion from $13.1–13.2 billion. Management attributed the increase to the Crinetics acquisition, which it expects to add $40–50 million this year.
• Operating expense guidance rose to about $6 billion from $5.65–5.75 billion, with about $250 million attributed to Crinetics. Non-GAAP SG&A rose 51% year on year.
• The FDA decision (PDUFA date) for povitacept in IgA nephropathy (IgAN) is 30 November 2026; management said the commercial team is ready to launch.

Bull case

• Diversification beyond CF. CEO Reshma Kewalramani said Vertex is moving to five commercial areas and cited guidance for more than $13 billion of 2026 revenue, against about $4 billion in 2019.
• Launch momentum. Chief commercial officer Duncan McKechnie reported CASGEVY revenue of $99 million (30% sequential growth) and more than 750 patients initiated since launch. JOURNAVX prescriptions exceeded 750,000 in the quarter, up more than 40% sequentially.
• Rare endocrinology. PALSONIFY contributed about $24 million for the full quarter ($10 million from September, after the Crinetics close). McKechnie said it holds a brand share above 40% among patients starting or switching therapy and is prescribed by roughly 500 endocrinologists.
• Povitacept. Management described a differentiated profile in efficacy, tolerability and dosing (0.46 mL, once every four weeks, at-home auto injector). Kewalramani said serious infections were balanced between povitacept and placebo arms, at 0.5% each, with no opportunistic infections.
• Pipeline. In the AMPLIFIED study, anaxaplin cut urine albumin-to-creatinine ratio by 42.7% in cohort 1; the pivotal AMPLITUDE interim analysis is expected early next year.

Bear case

• Costs and financing. Non-GAAP R&D was $936 million (up 9%) and SG&A $556 million (up 51%). The company took on $4.5 billion of term loans at about 4.8%, and said interest income will be about $60 million lower this year because of reduced cash.
• JOURNAVX revenue lags prescriptions. Revenue was $58 million (up 18% sequentially), against prescription growth above 40%, held back by a high gross-to-net deduction from the patient support program and a one-time reset after Medicare Part D access began in July. The program runs until mid-2027.
• Povitacept scrutiny. Cory Kasimov (Evercore) asked about an anonymous citizen petition concerning IgG monitoring and dose-hold rules. Goldman Sachs' Salveen Richter and Wells Fargo's Mohit Bansal asked about the manufacturer and the continuous manufacturing process.
• Competition in IgAN. Brian Abrahams (RBC) asked how uptake would be affected if many patients have already started a drug in the APRIL/BAFF class. Management did not give uptake figures and said it would provide metrics at the start of 2027.
• Next-generation CF correctors. Kewalramani called the VX-828 results excellent but said Vertex will wait for the other two molecules before choosing what to advance. In the dual regimen, VX-828 did not change sweat chloride versus the Trikafta baseline.

What management said

• "We are both excited and ready for our PDUFA date on November 30th." — Reshma Kewalramani, CEO.
• "A win would be a statistically significant result on the GFR slope." — Reshma Kewalramani, on the AMPLITUDE study.
• "We are 100% ready" — Duncan McKechnie, chief commercial officer, on the povitacept launch.
• "We have a high degree of certainty in our revenue guidance range." — Charles Wagner, CFO.

Risks

• Regulatory: the povitacept FDA decision on 30 November, including the label and the review of the manufacturing package. The citizen petition was raised by an analyst; Kewalramani said such petitions are common and this one was anonymous.
• Clinical: the AMPLITUDE interim analysis depends on a statistically significant eGFR-slope difference. Kewalramani said the FDA agreement is based on GFR, not proteinuria.
• Commercial: the timing of JOURNAVX net revenue, and CASGEVY infusion timing, which McKechnie said reflects patient choice with expected Q4 seasonality.
• Financial and integration: higher operating expenses, financing costs and lower interest income following the Crinetics acquisition.
• Pipeline choice: the decision between next-generation CF correctors is deferred until further data arrive next year.

Outlook

• Revenue: $13.15–13.25 billion for 2026. Management said the underlying drivers are unchanged, and that the $500 million-plus revenue goal for CASGEVY and JOURNAVX (plus four months of PALSONIFY) stands.
• Margin and expenses: full-year gross margin slightly below 86%; non-GAAP operating expenses of about $6 billion; non-GAAP tax rate of 19.5–20.5%; non-operating Crinetics financing costs of $105 million.
• Milestones: povitacept decision on 30 November; interim VX-670 data in myotonic dystrophy before year-end; AMPLITUDE interim results early next year; DPN pain phase 3 results around mid-2027; povitacept myasthenia gravis proof-of-concept data in the first half of 2027.
• Not committed to: a pivotal-stage choice among next-generation CF correctors, quantified povitacept uptake, or any 2027 financial guidance on this call.

Sources

• News: Investing.com, "TD Cowen raises Vertex stock price target on strong growth prospects", 3 Nov 2026
• Transcript: Vertex Pharmaceuticals (VRTX) Q3 2026 earnings call, 2 November 2026, via Financial Modeling Prep earnings transcript service (financialmodelingprep.com). Some speaker labels in the transcript were generic; the commercial remarks are attributed to Duncan McKechnie as introduced at the start of the call.
• Search of recent coverage on this site shows no earlier article on VRTX.